Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: The need for further revision of dose and schedule

Internal and Emergency Medicine

Volumn 8, Issue 5, 2013, Pages 417-423

  Magnani, Elena ^a   Farnetti, Enrico ^a   Nicoli, Davide ^a   Casali, Bruno ^a   Savoldi, Luisa ^a   Focaccetti, Chiara ^b   Boni, Corrado ^a   Albini, Adriana ^a   Banzi, Maria ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Dihydropyrimidine dehydrogenase (DPD); Dose reduction; Fluoropyrimidine chemotherapy; Toxicity; Tumors

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; ARTICLE; COLON TUMOR; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DOSE RESPONSE; GENETICS; HEAD AND NECK TUMOR; HETEROZYGOTE; HUMAN; MALE; METABOLISM; MUTATION; PATIENT SELECTION; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DEOXYCYTIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HETEROZYGOTE; HUMANS; MALE; MUTATION; PATIENT SELECTION; POLYMERASE CHAIN REACTION;

EID: 84880506829     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0936-8     Document Type: Article

References (26)

1. Punt CJ (1998) New drugs in the treatment of colorectal carcinoma. Cancer 83(4): 679-689.
2. Molteni LP, Rampinelli I, Cergnul M, Scaglietti U, Paino AM, Noonan DM, Bucci EO, Gottardi O, Albini A (2012) Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 16 Suppl 1: S45-S48.
3. Diasio RB, Lu Z (1994) Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12(11): 2239-2242.
4. Naguib FN, el Kouni MH, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45(11 Pt 1): 5405-5412.
5. van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC, Klumpen HJ, Maring JG, Derleyn VA, Maartense E, Milano G, Vijzelaar R, Gross E Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128(5): 529-538.
6. Amstutz U, Froehlich TK, Largiader CR Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9): 1321-1336.
7. van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7): 939-950.
8. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 67(1): 49-56.
9. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12): 4705-4712.
10. Meinsma R, Fernandez-Salguero P, van Kuilenburg AB, van Gennip AH, Gonzalez FJ (1995) Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 14(1): 1-6.
11. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98(3): 610-615.
12. Vreken P, van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, van Gennip AH (1996) A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 19(5): 645-654.
13. Vreken P, van Kuilenburg AB, Meinsma R, van Gennip AH (1997) Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis 20(3): 335-338.
14. van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, van Lenthe H, De Abreu RA, van Gennip AH (1998) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Adv Exp Med Biol 431: 293-298.
15. Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8(3): 132-138.
16. Mercier C, Ciccolini J (2006) Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 6(4): 288-296.
17. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7(5): 1149-1153.
18. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 89 (5): 662-673.
19. Albini A, Donatelli F, Focaccetti C, D'Elios MM, Noonan DM (2012) Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Intern Emerg Med 7: 399-401.
20. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S et al (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14-25.
21. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 7: 113-131.
22. Saif MW, Choma A, Salamone SJ, Chu E (2009) Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101(22): 1543-1552.
23. van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH (2002) High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7): 555-558.
24. Saif MW, Diasio R (2006) Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 5 (5): 359-362. 21.
25. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249 (2): 271-282.
26. Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G, Habboubi N, Garay C, Olivatto LO (2008) Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26(28): 4544-4550.